Insider Buying: Precision BioSciences (NASDAQ:DTIL) Director Acquires $12,690.00 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Stanley Frankel acquired 2,700 shares of Precision BioSciences stock in a transaction that occurred on Tuesday, December 16th. The stock was purchased at an average price of $4.70 per share, with a total value of $12,690.00. Following the transaction, the director owned 19,478 shares of the company’s stock, valued at $91,546.60. This trade represents a 16.09% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Stanley Frankel also recently made the following trade(s):

• On Friday, September 26th, Stanley Frankel bought 2,700 shares of Precision BioSciences stock. The shares were acquired at an average price of $4.97 per share, for a total transaction of $13,419.00.

Precision BioSciences Stock Performance

Shares of DTIL stock opened at $4.82 on Wednesday. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 1.35. The stock has a 50 day simple moving average of $5.94 and a 200-day simple moving average of $5.22. The company has a market cap of $63.91 million, a price-to-earnings ratio of -0.57 and a beta of 1.11. Precision BioSciences, Inc. has a 12-month low of $3.61 and a 12-month high of $8.82.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($1.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($1.53). The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $5.40 million. Precision BioSciences had a negative return on equity of 233.77% and a negative net margin of 11,977.36%.During the same period in the prior year, the company earned ($2.25) EPS. On average, equities analysts forecast that Precision BioSciences, Inc. will post -1.23 EPS for the current year.

Institutional Investors Weigh In On Precision BioSciences

Several hedge funds and other institutional investors have recently bought and sold shares of DTIL. Geode Capital Management LLC raised its position in shares of Precision BioSciences by 5.5% during the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after acquiring an additional 4,025 shares in the last quarter. Bridgeway Capital Management LLC acquired a new stake in Precision BioSciences in the second quarter worth about $260,000. Corient Private Wealth LLC acquired a new stake in shares of Precision BioSciences in the 2nd quarter worth approximately $425,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Precision BioSciences in the third quarter worth approximately $72,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Precision BioSciences by 21.5% in the third quarter. Vanguard Group Inc. now owns 492,596 shares of the company’s stock valued at $2,719,000 after buying an additional 87,242 shares during the period. 37.99% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Precision BioSciences in a report on Monday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $47.00.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.